ArticleCancers2023

Evaluation of Bortezomib-BeEAM (2BeEAM) as Chemotherapy Regimen Prior to ASCT in Patients with Mantle Cell Lymphoma.

Fabrizio Huwyler et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.